Intervacc AB (IVACC) Stock Overview

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. Its product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against Strep. suis for the treatment of piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. The company also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. Intervacc AB (publ) was incorporated in 1983 and is based in Hägersten, Sweden.